EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prime Medicine's enterprise value is $578.53 Mil.
Prime Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-186.64 Mil. Therefore, Prime Medicine's EV-to-EBITDA for today is -3.10.
The historical rank and industry rank for Prime Medicine's EV-to-EBITDA or its related term are showing as below:
PRME'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.57 Med: 0 Max: 0
Current: -3.1
PRME's EV-to-EBITDA is ranked worse than 100% of 460
companies
in the Biotechnology industry
Industry Median: 9.53
vs PRME: -3.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Prime Medicine EV-to-EBITDA Historical Data
The historical data trend for Prime Medicine's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Prime Medicine's EV-to-EBITDA
For the Biotechnology subindustry, Prime Medicine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prime Medicine's EV-to-EBITDA falls into.
Prime Medicine EV-to-EBITDA Calculation
Prime Medicine's EV-to-EBITDA for today is calculated as:
Prime Medicine's current Enterprise Value is $578.53 Mil.
Prime Medicine's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-186.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prime Medicine (NAS:PRME) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Prime Medicine's PE Ratio for today is calculated as:
Prime Medicine's share price for today is $5.61.
Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.180.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Prime Medicine's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Prime Medicine (Prime Medicine) Business Description
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRME has been successfully added to your 